التفاصيل البيبلوغرافية
العنوان:
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006
المؤلفون:
Scot Ebbinghaus , Christian U. Blank , Omid Hamid , James Larkin , Catriona M. McNeil , Adil Daud , Michal Lotem , Nageatte Ibrahim , Teresa M. Petrella , Caroline Robert , Jean-Jacques Grob , Laurent Mortier , Paul Lorigan , Georgina V. Long , Bart Neyns , Antoni Ribas , Matteo S. Carlino , Jacob Schachter , Ana Arance , Honghong Zhou
المساهمون:
Laboratory of Molecullar and Cellular Therapy, Laboratory of Molecular and Medical Oncology, Clinical sciences
بيانات النشر:
Lippincott Williams and Wilkins, 2016.
سنة النشر:
2016
مصطلحات موضوعية:
0301 basic medicine , Oncology , Cancer Research , medicine.medical_specialty , business.industry , Ipilimumab , Pembrolizumab , Surgery , Lower incidence , 03 medical and health sciences , 030104 developmental biology , 0302 clinical medicine , 030220 oncology & carcinogenesis , Internal medicine , Overall survival , Medicine , business , medicine.drug , Advanced melanoma
الوصف:
9504Background: In the phase III KEYNOTE-006 study (NCT01866319), pembro (anti–PD-1) provided superior OS and PFS and a lower incidence of grade 3-5 treatment-related AEs compared with ipi (anti–CT...
اللغة:
English
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23fc4539892dd1d07be846517f3d2e05Test https://biblio.vub.ac.be/vubir/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-survival-analysis-of-keynote006Test (2e1d8a74-0d96-4455-b3cc-da5df5908b2c).html
حقوق:
RESTRICTED
رقم الانضمام:
edsair.doi.dedup.....23fc4539892dd1d07be846517f3d2e05
قاعدة البيانات:
OpenAIRE
